Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2015 Dec 24

PMID 26693921

Citations 13

Authors

C Franchi

I Ardoino

R Rossio

A Nobili

E M Biganzoli

A Marengoni

M Marcucci

L Pasina

M Tettamanti

S Corrao

P M Mannucci

Affiliations

Soon will be listed here.

Abstract

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older).

Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) according to the Arizona Center for Education and Research on Therapeutics (AzCERT) classification. Specific drug combinations were also assessed.

Results: Among 3906 patients prescribed at least one drug at admission, 2156 (55.2%) were taking at least one QT-prolonging drug. Risk factors independently associated with the use of any QT-prolonging drugs were increasing age (odds ratio [OR] 1.02, 95% CI 1.01-1.03), multimorbidity (OR 2.69, 95% CI 2.33-3.10), hypokalemia (OR 2.79, 95% CI 1.32-5.89), atrial fibrillation (OR 1.66, 95% CI 1.40-1.98), and heart failure (OR 3.17, 95% CI 2.49-4.05). Furosemide, alone or in combination, was the most prescribed drug. Amiodarone was the most prescribed drug with a definite risk of TdP. Both the absolute number of QT-prolonging drugs (2890 vs. 3549) and the number of patients treated with them (2456 vs. 2156) increased at discharge. Among 1808 patients not prescribed QT-prolonging drugs at admission, 35.8% were prescribed them at discharge.

Conclusions: Despite their risk, QT-prolonging drugs are widely prescribed to hospitalized older persons. The curriculum for both practicing physicians and medical students should be strengthened to provide more education on the appropriate use of drugs in order to improve the management of hospitalized older people.

Citing Articles

Rapid changes of mRNA expressions of cardiac ion channels affected by Torsadogenic drugs influence susceptibility of rat hearts to arrhythmias induced by Beta-Adrenergic stimulation.

Hadova K, Kmecova J, Ochodnicka-Mackovicova K, Kralova E, Doka G, Pivackova L Pharmacol Res Perspect. 2023; 11(5):e01134.

PMID: 37715323 PMC: 10504435. DOI: 10.1002/prp2.1134.

QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.

Torres-Yaghi Y, Carwin A, Carolan J, Nakano S, Amjad F, Pagan F Neuropsychiatr Dis Treat. 2022; 17:3791-3818.

PMID: 34992373 PMC: 8714013. DOI: 10.2147/NDT.S324145.

Drug-Associated QTc Prolongation in Geriatric Hospitalized Patients: A Cross-Sectional Study in Internal Medicine.

Rossi M, Marzi F, Natale M, Porceddu A, Tuccori M, Lazzerini P Drugs Real World Outcomes. 2021; 8(3):325-335.

PMID: 33834380 PMC: 8324728. DOI: 10.1007/s40801-021-00234-x.

Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes.

Gnanapandithan K, Karthik N, Gerber J Clin Pract. 2021; 11(1):101-105.

PMID: 33562182 PMC: 7931031. DOI: 10.3390/clinpract11010015.

TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY.

Lakusic N, Slivnjak V, Ciglenecki N, Cerovec D Acta Clin Croat. 2020; 58(4):751-756.

PMID: 32665746 PMC: 7356489. DOI: 10.20471/acc.2019.58.04.23.

References

Bardai A, Amin A, Blom M, Bezzina C, Berdowski J, Langendijk P . Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J. 2013; 34(20):1506-16. DOI: 10.1093/eurheartj/eht054. View

Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C . Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011; 67(5):507-19. DOI: 10.1007/s00228-010-0977-0. View

Montanez A, Ruskin J, Hebert P, Lamas G, Hennekens C . Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004; 164(9):943-8. DOI: 10.1001/archinte.164.9.943. View

Burger C, Clase C, Gangji A . Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010; 89(9):1166-7. DOI: 10.1097/TP.0b013e3181d2fed7. View

Yap Y, Camm A . Drug induced QT prolongation and torsades de pointes. Heart. 2003; 89(11):1363-72. PMC: 1767957. DOI: 10.1136/heart.89.11.1363. View

Thomas A, Chan L, Bauman J, Olopade C . Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy. 1998; 18(2):381-5. View

Tay K, Ewald M, Bourgeois F . Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf. 2013; 23(1):9-17. DOI: 10.1002/pds.3455. View

Kounas S, Letsas K, Sideris A, Efraimidis M, Kardaras F . QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol. 2005; 28(5):472-3. DOI: 10.1111/j.1540-8159.2005.09348.x. View

Curtis L, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe N, Al-Khatib S . Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003; 114(2):135-41. DOI: 10.1016/s0002-9343(02)01455-9. View

10.

Samarendra P, Kumari S, Evans S, Sacchi T, Navarro V . QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol. 2001; 24(10):1572-4. DOI: 10.1046/j.1460-9592.2001.01572.x. View

11.

Straus S, Bleumink G, Dieleman J, van der Lei J, t Jong G, Kingma J . Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004; 164(12):1293-7. DOI: 10.1001/archinte.164.12.1293. View

12.

Shah S, Vanclay F, Cooper B . Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989; 42(8):703-9. DOI: 10.1016/0895-4356(89)90065-6. View

13.

Kazmierczak J, Peregud-Pogorzelska M, Rzeuski R . QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2007; 30(8):1043-6. DOI: 10.1111/j.1540-8159.2007.00809.x. View

14.

Letsas K, Sideris A, Kounas S, Efremidis M, Korantzopoulos P, Kardaras F . Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol. 2005; 109(2):273-4. DOI: 10.1016/j.ijcard.2005.04.031. View

15.

Pasina L, Djade C, Nobili A, Tettamanti M, Franchi C, Salerno F . Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013; 22(10):1054-60. DOI: 10.1002/pds.3510. View

16.

Ray W, Murray K, Hall K, Arbogast P, Stein C . Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20):1881-90. PMC: 3374857. DOI: 10.1056/NEJMoa1003833. View

17.

Charbit B, Alvarez J, Dasque E, Abe E, Demolis J, Funck-Brentano C . Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology. 2008; 109(2):206-12. DOI: 10.1097/ALN.0b013e31817fd8c8. View

18.

Nachimuthu S, Assar M, Schussler J . Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2014; 3(5):241-53. PMC: 4110870. DOI: 10.1177/2042098612454283. View

19.

Mannucci P, Nobili A . Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014; 9(7):723-34. DOI: 10.1007/s11739-014-1124-1. View

20.

Onder G, Bonassi S, Abbatecola A, Folino-Gallo P, Lapi F, Marchionni N . High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci. 2013; 69(4):430-7. DOI: 10.1093/gerona/glt118. View